Structures by: Vishweshwar P.
Total: 99
2,3,5-Pyrazine tricarboxylic acid dihydrate
C7H4N2O6.2H2O
The Journal of Physical Chemistry A (2004) 108, 43 9406
a=5.2830(3)Å b=6.6497(3)Å c=13.8423(7)Å
α=93.064(2)° β=90.513(2)° γ=103.009(2)°
2,3,5,6-pyrazinetetracarboxylic acid dihydrate
C8H4N2O8.2H2O
The Journal of Physical Chemistry A (2004) 108, 43 9406
a=5.4385(10)Å b=6.3885(10)Å c=8.6809(10)Å
α=98.381(5)° β=107.406(5)° γ=105.573(5)°
2,3,5,6-pyrazinetetracarboxylic acid dihydrate
C8H4N2O8,2H2O
The Journal of Physical Chemistry A (2004) 108, 43 9406
a=5.4361(10)Å b=6.3699(10)Å c=8.6672(10)Å
α=97.911(5)° β=107.546(5)° γ=105.718(5)°
2,3,5,6-pyrazinetetracarboxylic acid dihydrate
C8H4N2O8,2H2O
The Journal of Physical Chemistry A (2004) 108, 43 9406
a=5.4606(10)Å b=6.4133(10)Å c=8.7164(10)Å
α=98.962(5)° β=107.408(5)° γ=105.348(5)°
2,3,5,6-pyrazinetetracarboxylic acid dihydrate
C8H4N2O8,2H2O
The Journal of Physical Chemistry A (2004) 108, 43 9406
a=5.4950(10)Å b=6.4410(10)Å c=8.7670(10)Å
α=99.393(6)° β=107.565(7)° γ=105.174(7)°
2,3-Pyrazine dicarboxylic acid dihydrate
C6H4N2O4.2H2O
The Journal of Physical Chemistry A (2004) 108, 43 9406
a=5.3470(2)Å b=13.0286(4)Å c=11.7443(4)Å
α=90.00° β=99.0360(10)° γ=90.00°
C19H15N3O
C19H15N3O
Molecular Pharmaceutics (2007) 4, 3 401
a=18.715(8)Å b=7.228(3)Å c=23.208(9)Å
α=90.00° β=90.478(12)° γ=90.00°
C18H14N2O
C18H14N2O
Molecular Pharmaceutics (2007) 4, 3 401
a=9.906(12)Å b=21.65(3)Å c=7.590(9)Å
α=90.00° β=112.14(2)° γ=90.00°
C18H14N2O
C18H14N2O
Molecular Pharmaceutics (2007) 4, 3 401
a=26.217(13)Å b=7.481(5)Å c=19.410(10)Å
α=90.00° β=128.310(14)° γ=90.00°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=12.7871(17)Å b=7.2838(9)Å c=44.445(6)Å
α=90.00° β=90.895(3)° γ=90.00°
C19H15N3O
C19H15N3O
Molecular Pharmaceutics (2007) 4, 3 401
a=18.503(3)Å b=7.5019(10)Å c=21.971(3)Å
α=90.00° β=92.181(4)° γ=90.00°
C19H15N3O
C19H15N3O
Molecular Pharmaceutics (2007) 4, 3 401
a=7.616(2)Å b=10.003(3)Å c=22.497(6)Å
α=87.342(5)° β=81.024(6)° γ=69.737(6)°
C26H22N4O2
C26H22N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=13.223(3)Å b=6.1971(12)Å c=14.630(3)Å
α=90.00° β=113.661(3)° γ=90.00°
C26H20N4O2
C26H20N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=16.5421(17)Å b=7.5056(8)Å c=18.709(2)Å
α=90.00° β=106.763(2)° γ=90.00°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=20.866(6)Å b=7.437(2)Å c=6.7662(18)Å
α=90.00° β=98.142(5)° γ=90.00°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=3.8483(17)Å b=8.755(4)Å c=14.364(6)Å
α=96.647(7)° β=94.498(8)° γ=95.474(7)°
C26H22N4O2
C26H22N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=11.195(3)Å b=7.335(2)Å c=13.530(4)Å
α=90.00° β=99.465(7)° γ=90.00°
C26H20N4O2
C26H20N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=14.660(3)Å b=4.1100(8)Å c=18.290(4)Å
α=90.00° β=90.74(3)° γ=90.00°
C24H18N6O3
C24H18N6O3
Molecular Pharmaceutics (2007) 4, 3 401
a=7.889(3)Å b=8.156(3)Å c=19.673(7)Å
α=83.866(7)° β=85.627(6)° γ=63.512(5)°
C24H18N4O2
C24H18N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=39.87(2)Å b=7.586(5)Å c=6.915(4)Å
α=90.00° β=91.972(19)° γ=90.00°
C18H14N4O2
C18H14N4O2
Molecular Pharmaceutics (2007) 4, 3 401
a=9.171(4)Å b=9.941(5)Å c=10.265(5)Å
α=95.674(8)° β=94.987(8)° γ=114.784(8)°
C30H24F4N4O4S
C30H24F4N4O4S
Molecular Pharmaceutics (2007) 4, 3 401
a=8.274(3)Å b=10.172(3)Å c=18.601(7)Å
α=87.521(7)° β=78.256(6)° γ=71.067(7)°
1:2 molecular complex of 5,5-diethylbarbituric acid and acridine
C34H30N4O3
Chemical Communications (2002) 17 1830-1831
a=18.249(4)Å b=16.260(3)Å c=10.053(2)Å
α=90.00° β=111.47(3)° γ=90.00°
1:1 molecular complex of 5,5-diethylbarbituric acid and 1,10-phenanthroline
C20H20N4O3
Chemical Communications (2002) 17 1830-1831
a=12.656(3)Å b=7.0140(14)Å c=20.665(4)Å
α=90.00° β=98.31(3)° γ=90.00°
1:1 molecular complex of 5,5-diethylbarbituric acid and 1,3,5,7- hexamethylenetetramine
C14H24N6O3
Chemical Communications (2002) 17 1830-1831
a=10.866(2)Å b=13.263(3)Å c=22.634(5)Å
α=90.00° β=90.00° γ=90.00°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=13.039(7)Å b=7.401(4)Å c=22.560(12)Å
α=90° β=102.440(5)° γ=90°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=10.5495(11)Å b=10.3154(9)Å c=10.2205(11)Å
α=90° β=109.904(4)° γ=90°
1:1 co-crystal of 2-oxo-1-pyrrolidinyl)acetamide and 2,5- dihydroxybenzoic acid'
C6H10N2O2,C7H6O4
Chemical Communications (2005) 36 4601-4603
a=27.896(3)Å b=5.1762(5)Å c=19.7879(18)Å
α=90.00° β=101.090(2)° γ=90.00°
1:1 Co-crystal of 2-Oxo-1-pyrrolidinyl)acetamide and 4- Hydroxybenzoic acid
C6H10N2O2,C7H6O3
Chemical Communications (2005) 36 4601-4603
a=14.780(3)Å b=5.5029(12)Å c=17.068(4)Å
α=90.00° β=109.557(4)° γ=90.00°
1:1 molecular complex of 4-hydroxybenzoic acid and isonicotinamide
C7H6O3,C6H6N2O
CrystEngComm (2003) 5, 31 164
a=6.0729(1)Å b=9.4013(2)Å c=20.6723(4)Å
α=90.00° β=95.2870(10)° γ=90.00°
1:2 molecular complex of resorcinol and isonicotinamide
2(C6H6N2O),C6H6O2
CrystEngComm (2003) 5, 31 164
a=7.0307(1)Å b=10.7052(2)Å c=11.9562(2)Å
α=87.7550(10)° β=82.7350(10)° γ=73.8350(10)°
1:2 molecular complex of phloroglucinol and isonicotinamide dihydrate
2(C6H6N2O),C6H6O3,2(H2O)
CrystEngComm (2003) 5, 31 164
a=7.4967(1)Å b=8.8748(1)Å c=15.2793(3)Å
α=95.1886(6)° β=97.4790(6)° γ=105.7701(7)°
1:2 molecular complex of hydroquinone and isonicotinamide
C6H6N2O,0.5(C6H6O2)
CrystEngComm (2003) 5, 31 164
a=14.2811(4)Å b=5.4136(2)Å c=11.9110(3)Å
α=90.00° β=111.9340(10)° γ=90.00°
1,2-bis(4-pyridinium)ethane saccharinate (1:2)
C12H14N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=7.5770(8)Å b=11.0722(13)Å c=15.260(2)Å
α=90° β=90.809(11)° γ=90°
1,2-bis(4-pyridinium)ethylene saccharinate (1:2)
C12H12N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=13.161(2)Å b=5.251(2)Å c=18.590(12)Å
α=90° β=106.828(3)° γ=90°
C4H12N2,2(C7H4NO3S)
C4H12N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=11.1261(10)Å b=9.3971(8)Å c=9.6281(10)Å
α=90.0000° β=99.489(4)° γ=90.0000°
1,4-Dimethylpiperazinium saccharinate (1:2)
C6H16N2,2(C7H4NO3S)
CrystEngComm (2008) 10, 8 996
a=7.973(2)Å b=15.413(3)Å c=9.293(2)Å
α=90° β=104.555(10)° γ=90°
2,2'-dipyridiniumamine saccharinate (1:1)
C10H10N3,C7H4NO3S
CrystEngComm (2008) 10, 8 996
a=9.635(2)Å b=13.385(4)Å c=14.149(3)Å
α=105.658(3)° β=91.773(2)° γ=110.444(2)°
C16H24N5O,C6H4NO2,CH4O
C16H24N5O,C6H4NO2,CH4O
CrystEngComm (2008) 10, 3 283
a=9.7496(9)Å b=19.3384(12)Å c=13.2982(10)Å
α=90.0000° β=103.445(3)° γ=90.0000°
C16H23N5O
C16H23N5O
CrystEngComm (2008) 10, 3 283
a=7.395(4)Å b=11.218(6)Å c=20.202(10)Å
α=90.0000° β=90.0000° γ=90.0000°
C16H25N5O2
C16H25N5O2
CrystEngComm (2008) 10, 3 283
a=7.111(3)Å b=10.857(5)Å c=23.106(10)Å
α=90.0000° β=93.241(4)° γ=90.0000°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=10.5495(11)Å b=10.3154(9)Å c=10.2205(11)Å
α=90° β=109.904(4)° γ=90°
C8H12N2,2(C7H6O3)
C8H12N2,2(C7H6O3)
Chemical Communications (Cambridge, United Kingdom) (2007) 23 2375-2377
a=13.039(7)Å b=7.401(4)Å c=22.560(12)Å
α=90° β=102.440(5)° γ=90°
(3<i>S</i>,4<i>R</i>)-4-(4-Fluorophenyl)-3-(hydroxymethyl)piperidinium chloride
C12H17FNO,Cl
Acta Crystallographica Section E (2008) 64, 5 o800
a=7.697(4)Å b=5.958(3)Å c=13.393(8)Å
α=90° β=95.505(5)° γ=90°
(S)-3-(Ammoniomethyl)-5-methylhexanoate
C8H17NO2
Acta Crystallographica Section C (2007) 63, 5 o306-o308
a=6.4641(4)Å b=7.8224(5)Å c=18.6122(13)Å
α=90° β=90° γ=90°
2,3-Pyrazinedicarboxamide
C6H6N4O2
Acta Crystallographica Section C (2000) 56, 12 1512-1514
a=5.0250(3)Å b=7.0977(3)Å c=10.1196(5)Å
α=70.826(3)° β=81.868(3)° γ=81.163(3)°
1-[(4<i>S</i>)-4-Benzyl-2-thioxo-1,3-thiazolidin-3-yl]propan-1-one
C13H15NOS2
Acta Crystallographica Section E (2009) 65, 9 o2159
a=8.850(6)Å b=7.189(5)Å c=10.595(7)Å
α=90° β=95.537(6)° γ=90°
Calophyllolide
C26H24O5
Acta Crystallographica Section E (2010) 66, 5 o1115
a=8.943(3)Å b=11.559(4)Å c=12.171(3)Å
α=96.238(8)° β=104.041(5)° γ=110.301(8)°
(<i>R</i>)-(+)-2-{[(3-Methyl-4-nitropyridin-2-yl)methyl]sulfinyl}- 1<i>H</i>-benzimidazole
C14H12N4O3S
Acta Crystallographica Section E (2011) 67, 8 o2190
a=7.7422(13)Å b=11.0505(15)Å c=8.2318(13)Å
α=90.0000° β=103.697(7)° γ=90.0000°
2:3 co-crystal Form I of Trimesic acid and 1,2-bis(4-pyridyl)ethane
3(C12H12N2),2(C9H6O6)
Crystal Growth & Design (2009) 9, 2 1106
a=19.270(3)Å b=19.906(3)Å c=25.249(3)Å
α=90.00° β=90.00° γ=90.00°
1:1 Co-crystal of Aspirin and Carbamazepine
C15H12N2O,C9H8O4
Journal of the American Chemical Society (2005)
a=9.0317(18)Å b=11.364(2)Å c=11.424(2)Å
α=60.350(4)° β=85.599(4)° γ=84.724(4)°
Form-II of Aspirin
C9H8O4
Journal of the American Chemical Society (2005)
a=12.095(7)Å b=6.491(4)Å c=11.323(6)Å
α=90.00° β=111.509(9)° γ=90.00°
2,4-Dimethoxy-6-morpholin-4-yl-[1,3,5]triazine
C9H14N4O3
Journal of the American Chemical Society (2005)
a=10.258(2)Å b=9.2156(18)Å c=14.158(5)Å
α=90.00° β=125.930(20)° γ=90.00°
C44H40Br2N2O4
C44H40Br2N2O4
Journal of the American Chemical Society (2005)
a=19.3272(7)Å b=11.6860(5)Å c=16.0890(6)Å
α=90.00° β=92.6300(10)° γ=90.00°
4-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-morpholin-4-ium; tetrafluoro borate
C10H17N4O3,BF4
Journal of the American Chemical Society (2005)
a=6.59250(10)Å b=10.65520(10)Å c=21.2960(2)Å
α=90.00° β=90.00° γ=90.00°
1:1 Co-crystal of 4HBA + 4PP
C11H9N,C7H6O3
Crystal Growth & Design (2008) 8, 12 4533
a=26.780(4)Å b=7.445(2)Å c=19.471(3)Å
α=90.00° β=131.101(2)° γ=90.00°
1:2 Co-crystal of 3HBA + 4PP
C7H6O3,2(C11H9N)
Crystal Growth & Design (2008) 8, 12 4533
a=9.203(16)Å b=20.819(4)Å c=11.827(2)Å
α=90.00° β=93.487(3)° γ=90.00°
1:1 Co-crystal of 3HBA + BPEA
C12H12N2,C7H6O3
Crystal Growth & Design (2008) 8, 12 4533
a=7.981(15)Å b=8.931(17)Å c=11.209(2)Å
α=97.585(3)° β=90.745(4)° γ=90.665(4)°
1:1 Co-crystal of 3HBA + BP
C10H8N2,C7H6O3
Crystal Growth & Design (2008) 8, 12 4533
a=8.197(12)Å b=8.883(12)Å c=10.361(15)Å
α=72.213(3)° β=72.678(2)° γ=86.773(3)°
2:1 Co-crystal of 3HBA + Pyrazine
C7H6O3,0.5(C4H4N2)
Crystal Growth & Design (2008) 8, 12 4533
a=5.201(11)Å b=14.568(3)Å c=10.994(3)Å
α=90.00° β=100.45(5)° γ=90.00°
2:1:2 Co-crystal of 4HBA + TMP + CH3CN
C7H6O3,0.5(C8H12N2),C2H3N
Crystal Growth & Design (2008) 8, 12 4533
a=11.693(4)Å b=8.694(3)Å c=12.722(4)Å
α=90.00° β=94.920(7)° γ=90.00°
2:1 Co-crystal of 4HBA + Pyrazine
C7H6O3,0.5(C4H4N2)
Crystal Growth & Design (2008) 8, 12 4533
a=5.942(9)Å b=6.818(10)Å c=10.638(16)Å
α=102.963(3)° β=97.383(2)° γ=100.057(3)°
1:1 Co-crystal of 3HBA + Quinoxaline
C7H6O3,C8H6N2
Crystal Growth & Design (2008) 8, 12 4533
a=7.2850(9)Å b=12.147(15)Å c=14.432(18)Å
α=87.837(2)° β=85.937(2)° γ=80.916(2)°
2:3 Co-crystal of 3HBA + TMP
C7H6O3,1.5(C8H12N2)
Crystal Growth & Design (2008) 8, 12 4533
a=9.461(14)Å b=17.807(3)Å c=11.081(17)Å
α=90.00° β=92.184(3)° γ=90.00°
1:1 Co-crystal of 6HNA + BPEE
C12H10N2,C11H8O3
Crystal Growth & Design (2008) 8, 12 4533
a=5.9682(8)Å b=8.7387(12)Å c=17.938(3)Å
α=78.473(2)° β=82.090(3)° γ=88.921(3)°
1:1 Co-crystal of 4HBA + BPEE
C12H10N2,C7H6O3
Crystal Growth & Design (2008) 8, 12 4533
a=6.193(19)Å b=6.957(2)Å c=18.499(5)Å
α=95.046(6)° β=94.058(7)° γ=103.928(6)°
1:1 Co-crystal of 3HBA + BPEE
C12H10N2,C7H6O3
Crystal Growth & Design (2008) 8, 12 4533
a=7.901(13)Å b=10.310(16)Å c=10.863(17)Å
α=114.081(2)° β=103.883(3)° γ=93.041(3)°
1:1 complex of 3HP + IPT
C8H5O4,C5H6N1O1
Crystal Growth & Design (2008) 8, 12 4533
a=10.218(5)Å b=11.001(6)Å c=10.412(5)Å
α=90.00° β=99.983(9)° γ=90.00°
Ethylammonium Cyclohexane-3cis,5cis-dicarboxylic acid-1-carboxylate
(C9H11O6)(C2H8N)
Crystal Growth & Design (2005) 5, 3 1271
a=7.6682(9)Å b=8.4743(10)Å c=9.5164(12)Å
α=91.741(2)° β=94.436(2)° γ=97.239(2)°
Hydrazinium Cyclohexane-3cis,5cis-dicarboxylic acid-1-carboxylate
(C9H11O6)(N2H5)
Crystal Growth & Design (2005) 5, 3 1271
a=5.4329(14)Å b=17.829(5)Å c=11.820(3)Å
α=90.00° β=94.361(5)° γ=90.00°
Sodium Cyclohexane-3cis,5cis-dicarboxylic acid-1-carboxylate
(C9H11O6)Na
Crystal Growth & Design (2005) 5, 3 1271
a=9.2006(14)Å b=4.9116(8)Å c=21.385(3)Å
α=90.00° β=96.835(5)° γ=90.00°
Hydroxylammonium Cyclohexane-3cis,5cis-dicarboxylic acid-1-carboxylate
(C9H11O6)(NH4O)
Crystal Growth & Design (2005) 5, 3 1271
a=5.0737(14)Å b=18.203(5)Å c=11.742(3)Å
α=90.00° β=93.275(4)° γ=90.00°
Methylammonium cyclohexane-1-carboxylate-3cis,5-cis-dicarboxylic acid
(C9H11O6)(CH6N)
Crystal Growth & Design (2005) 5, 3 1271
a=5.8655(12)Å b=17.805(4)Å c=11.408(2)Å
α=90.00° β=93.70(3)° γ=90.00°
Ammonium cyclohexane-1-carboxylate-3cis,5cis-dicarboxylic acid
(C9H11O6)(NH4)
Crystal Growth & Design (2005) 5, 3 1271
a=4.7608(11)Å b=19.703(5)Å c=11.502(3)Å
α=90.00° β=90.551(4)° γ=90.00°
2:3 co-crystal Form I of Trimesic acid and 1,2-bis(4-pyridyl)ethane
3(C12H12N2),2(C9H6O6)
Crystal Growth & Design (2005) 5, 6 2046
a=19.270(3)Å b=19.906(3)Å c=25.249(3)Å
α=90.00° β=90.00° γ=90.00°
2:3 co-crystal Form II of Trimesic acid and 1,2-bis(4-pyridyl)ethane
3(C12H12N2),2(C9H6O6)
Crystal Growth & Design (2005) 5, 6 2046
a=10.344(2)Å b=12.313(2)Å c=18.914(4)Å
α=90.00° β=94.309(4)° γ=90.00°
1,3,5-Cyclohexane tricarboxylic acid mono hydrate
C9H14O7
Crystal Growth & Design (2002) 2, 5 325
a=22.255(14)Å b=6.890(4)Å c=16.204(12)Å
α=90.00° β=118.34(3)° γ=90.00°
2:3 complex of 1,3,5-cyclohexane tricarboxylic acid and 4,4'-bypyridine mono hydrate
C48H50N6O13
Crystal Growth & Design (2002) 2, 5 325
a=10.5609(4)Å b=14.2226(6)Å c=16.9229(7)Å
α=113.2930(10)° β=102.5530(10)° γ=93.8520(10)°
C12H12N2,2(C7H6O2)
C12H12N2,2(C7H6O2)
Crystal Growth & Design (2009) 9, 2 1106
a=6.4357(17)Å b=6.8960(18)Å c=12.412(3)Å
α=79.037(5)° β=80.952(5)° γ=80.144(5)°
C40H38N2O6
C40H38N2O6
Crystal Growth & Design (2009) 9, 2 1106
a=5.7645(16)Å b=7.607(2)Å c=19.109(5)Å
α=84.851(5)° β=83.797(5)° γ=89.241(5)°
C24H20N2O2
C24H20N2O2
Crystal Growth & Design (2009) 9, 2 1106
a=11.7712(19)Å b=5.9268(9)Å c=13.954(2)Å
α=90.00° β=108.614(3)° γ=90.00°
C12H10N2,C6H6O2
C12H10N2,C6H6O2
Crystal Growth & Design (2009) 9, 2 1106
a=6.000(2)Å b=17.265(6)Å c=7.062(2)Å
α=90.00° β=92.296(6)° γ=90.00°
C8H12N2,C2H2O4
C8H12N2,C2H2O4
Crystal Growth & Design (2009) 9, 2 1106
a=3.8081(9)Å b=8.3558(19)Å c=8.606(2)Å
α=81.950(4)° β=80.337(4)° γ=85.847(4)°
C12H10N2,2(C10H8O)
C12H10N2,2(C10H8O)
Crystal Growth & Design (2009) 9, 2 1106
a=6.8699(7)Å b=25.450(3)Å c=7.6379(8)Å
α=90.00° β=110.106(2)° γ=90.00°
C14H18N2O2
C14H18N2O2
Crystal Growth & Design (2009) 9, 2 1106
a=7.566(2)Å b=9.218(2)Å c=10.001(3)Å
α=90.00° β=111.328(5)° γ=90.00°
C12H12N2,C5H8O4
C12H12N2,C5H8O4
Crystal Growth & Design (2009) 9, 2 1106
a=12.295(3)Å b=11.166(2)Å c=24.421(5)Å
α=90.00° β=97.102(4)° γ=90.00°
C36H48N6O4
C36H48N6O4
Crystal Growth & Design (2009) 9, 2 1106
a=9.0768(11)Å b=11.7248(14)Å c=17.443(2)Å
α=98.097(2)° β=98.195(2)° γ=106.019(2)°
C12H12N2,2(C10H8O)
C12H12N2,2(C10H8O)
Crystal Growth & Design (2009) 9, 2 1106
a=6.9691(15)Å b=25.182(5)Å c=7.7714(16)Å
α=90.00° β=111.272(4)° γ=90.00°
C12H12N2,C8H6O4
C12H12N2,C8H6O4
Crystal Growth & Design (2009) 9, 2 1106
a=6.9526(17)Å b=7.4920(18)Å c=17.118(4)Å
α=100.783(4)° β=90.162(4)° γ=101.822(4)°
C12H11NO
C12H11NO
Crystal Growth & Design (2009) 9, 2 1106
a=11.6591(16)Å b=5.9135(8)Å c=14.087(2)Å
α=90.00° β=107.618(2)° γ=90.00°
C10H8N2,C7H6O2
C10H8N2,C7H6O2
Crystal Growth & Design (2009) 9, 2 1106
a=7.608(2)Å b=11.454(3)Å c=16.423(5)Å
α=100.293(5)° β=95.987(6)° γ=90.521(5)°
C26H32N4O2
C26H32N4O2
Crystal Growth & Design (2009) 9, 2 1106
a=15.579(3)Å b=8.5123(19)Å c=17.781(4)Å
α=90.00° β=93.686(6)° γ=90.00°
3:2 co-crystal of 4,4'-biphenol and 2-aminopyridine
C23H21N2O3
Crystal Growth & Design (2006) 6, 12 2648
a=11.3359(16)Å b=20.632(3)Å c=8.0994(12)Å
α=90.00° β=94.359(3)° γ=90.00°
1:2 Co-crystal of 4,4'-biphenol and caprolactam
C12H10O2,2(C6H11NO)
Crystal Growth & Design (2006) 6, 12 2648
a=6.6784(9)Å b=15.130(2)Å c=22.084(3)Å
α=90.00° β=92.200(2)° γ=90.00°
1:2 co-crystal of resorcinol and caprolactam
C18H18N2O3
Crystal Growth & Design (2006) 6, 12 2648
a=6.5876(13)Å b=9.3924(19)Å c=16.172(3)Å
α=76.124(4)° β=79.358(4)° γ=78.071(4)°
1:2 Acetic acid solvate of Trimesic acid
2(C9H6O6),C2H4O2
Crystal Growth & Design (2006) 6, 11 2429
a=15.4523(14)Å b=16.3494(15)Å c=16.5130(14)Å
α=119.409(2)° β=90.449(2)° γ=117.4810(10)°
2:1 Complex of 4HBA + BPEA
C7H6O3,C7H5O3,C12H13N2
Crystal Growth & Design (2008) 8, 12 4533
a=7.367(9)Å b=23.716(3)Å c=12.552(15)Å
α=90.00° β=103.033(2)° γ=90.00°
1:1 Complex of 3HPY + BA
C7H5O2,C5H6N1O1
Crystal Growth & Design (2008) 8, 12 4533
a=5.038(4)Å b=10.012(8)Å c=10.362(8)Å
α=90.00° β=100.330(15)° γ=90.00°
C12H10N2,C5H8O4
C12H10N2,C5H8O4
Crystal Growth & Design (2009) 9, 2 1106
a=15.562(6)Å b=10.281(4)Å c=9.436(4)Å
α=90.00° β=92.357(7)° γ=90.00°